View in EDS

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.

Saved in:
Bibliographic Details
Title: Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.
Authors: Rinderknecht E; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Urology, University Hospital Augsburg, Augsburg, Germany. Electronic address: emily.rinderknecht@uk-augsburg.de., Bielstein G; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Cathomas R; Department of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland., Schlack K; Department of Urology, University Hospital Münster, Münster, Germany., Bastian JLD; Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany., Darr C; Department of Urology, West German Cancer Center, University of Duisburg, German Cancer Consortium, University Hospital Essen, Essen, Germany., Unland-Gies D; Department of Urology, University Hospital, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany., Kappler P; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Paffenholz P; Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Cologne Germany; Center for Integrated Oncology (CIO) Köln-Bonn, Cologne, Germany., Richter J; Department of Medical Oncology and Internal Medicine VI, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany., Müller M; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany., Seitz AK; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany., Steinestel J; Department of Urology, University Hospital Augsburg, Augsburg, Germany., Heidegger I; Department of Urology, Medical University Innsbruck, Innsbruck, Austria., Burger M; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Breyer J; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Schnabel MJ; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Source: Urologic oncology [Urol Oncol] 2026 Apr; Vol. 44 (4), pp. 111028. Date of Electronic Publication: 2026 Feb 20.
Publication Type: Journal Article; Multicenter Study; Comparative Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41722488
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Rinderknecht+E%22">Rinderknecht E</searchLink>; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Urology, University Hospital Augsburg, Augsburg, Germany. Electronic address: emily.rinderknecht@uk-augsburg.de.<br /><searchLink fieldCode="AU" term="%22Bielstein+G%22">Bielstein G</searchLink>; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Cathomas+R%22">Cathomas R</searchLink>; Department of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schlack+K%22">Schlack K</searchLink>; Department of Urology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Bastian+JLD%22">Bastian JLD</searchLink>; Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany.<br /><searchLink fieldCode="AU" term="%22Darr+C%22">Darr C</searchLink>; Department of Urology, West German Cancer Center, University of Duisburg, German Cancer Consortium, University Hospital Essen, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Unland-Gies+D%22">Unland-Gies D</searchLink>; Department of Urology, University Hospital, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.<br /><searchLink fieldCode="AU" term="%22Kappler+P%22">Kappler P</searchLink>; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.<br /><searchLink fieldCode="AU" term="%22Paffenholz+P%22">Paffenholz P</searchLink>; Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Cologne Germany; Center for Integrated Oncology (CIO) Köln-Bonn, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Richter+J%22">Richter J</searchLink>; Department of Medical Oncology and Internal Medicine VI, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Müller+M%22">Müller M</searchLink>; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.<br /><searchLink fieldCode="AU" term="%22Seitz+AK%22">Seitz AK</searchLink>; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Steinestel+J%22">Steinestel J</searchLink>; Department of Urology, University Hospital Augsburg, Augsburg, Germany.<br /><searchLink fieldCode="AU" term="%22Heidegger+I%22">Heidegger I</searchLink>; Department of Urology, Medical University Innsbruck, Innsbruck, Austria.<br /><searchLink fieldCode="AU" term="%22Burger+M%22">Burger M</searchLink>; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Breyer+J%22">Breyer J</searchLink>; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Schnabel+MJ%22">Schnabel MJ</searchLink>; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229805460%22">Urologic oncology</searchLink> [Urol Oncol] 2026 Apr; Vol. 44 (4), pp. 111028. <i>Date of Electronic Publication: </i>2026 Feb 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Multicenter Study; Comparative Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9805460 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2496 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210781439%22">10781439 </searchLink><i>NLM ISO Abbreviation: </i>Urol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41722488
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.urolonc.2026.111028
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 111028
    Titles:
      – TitleFull: Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rinderknecht E
      – PersonEntity:
          Name:
            NameFull: Bielstein G
      – PersonEntity:
          Name:
            NameFull: Cathomas R
      – PersonEntity:
          Name:
            NameFull: Schlack K
      – PersonEntity:
          Name:
            NameFull: Bastian JLD
      – PersonEntity:
          Name:
            NameFull: Darr C
      – PersonEntity:
          Name:
            NameFull: Unland-Gies D
      – PersonEntity:
          Name:
            NameFull: Kappler P
      – PersonEntity:
          Name:
            NameFull: Paffenholz P
      – PersonEntity:
          Name:
            NameFull: Richter J
      – PersonEntity:
          Name:
            NameFull: Müller M
      – PersonEntity:
          Name:
            NameFull: Seitz AK
      – PersonEntity:
          Name:
            NameFull: Steinestel J
      – PersonEntity:
          Name:
            NameFull: Heidegger I
      – PersonEntity:
          Name:
            NameFull: Burger M
      – PersonEntity:
          Name:
            NameFull: Breyer J
      – PersonEntity:
          Name:
            NameFull: Schnabel MJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2026 Apr
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1873-2496
          Numbering:
            – Type: volume
              Value: 44
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Urologic oncology
              Type: main
ResultId 1